Model‐informed drug development supporting the approval of the avelumab flat‐dose regimen in patients with advanced renal cell carcinoma

Avelumab is an anti–PD‐L1 monoclonal antibody approved as monotherapy for Merkel cell carcinoma (MCC) and urothelial carcinoma (UC), and in combination with axitinib for advanced renal cell carcinoma (aRCC). Although initially approved with weight‐based dosing (10 mg/kg intravenously [IV] every 2 we...

Descripción completa

Detalles Bibliográficos
Autores principales: Masters, Joanna C., Khandelwal, Akash, di Pietro, Alessandra, Dai, Haiqing, Brar, Satjit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007597/
https://www.ncbi.nlm.nih.gov/pubmed/35166465
http://dx.doi.org/10.1002/psp4.12771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007597/
https://www.ncbi.nlm.nih.gov/pubmed/35166465
http://dx.doi.org/10.1002/psp4.12771

Ejemplares similares